ClinicalTrials.gov
ClinicalTrials.gov Menu

Open Label Study of Long Term Safety Evaluation of Alirocumab (ODYSSEY OLE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01954394
Recruitment Status : Completed
First Posted : October 1, 2013
Results First Posted : July 24, 2018
Last Update Posted : July 24, 2018
Sponsor:
Collaborator:
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
Sanofi

September 16, 2013
October 1, 2013
June 29, 2018
July 24, 2018
July 24, 2018
December 17, 2013
June 30, 2017   (Final data collection date for primary outcome measure)
Percentage of Participants Who Experienced Adverse Events (AEs) [ Time Frame: Up to 10 weeks after last study drug administration (maximum of 176 weeks) ]
Reported AEs are treatment-emergent AEs that is AEs that developed/worsened during the 'treatment-emergent period' (the time from the first dose of alirocumab in this study up to the last dose of alirocumab received in this study +70 days). Clinically significant lab and vital sign abnormalities were to be reported as AEs.
Assessment of safety parameters (adverse events, laboratory data, vital signs) [ Time Frame: Up to 120 weeks ]
Complete list of historical versions of study NCT01954394 on ClinicalTrials.gov Archive Site
  • Percent Change From Baseline in Calculated LDL-C at Weeks 8, 24, 48, 72, 96, 120, 144 and 168 [ Time Frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168 ]
    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
  • Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168 [ Time Frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168 ]
    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
  • Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168 [ Time Frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168 ]
    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
  • Percentage of Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) Over Time [ Time Frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168 ]
    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
  • Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) Over Time [ Time Frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168 ]
    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
  • Percentage of Participants With Calculated LDL-C <70 mg/dL (1.81mmol/L) and/or >=50% Reduction in Calculated LDL-C From Baseline (if Calculated LDL-C >=70 mg/dL [1.81mmol/L]) Over Time [ Time Frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168 ]
    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
  • Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168 [ Time Frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168 ]
    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
  • Percent Change From Baseline in Total-cholesterol at Weeks 8, 24, 48, 72, 96, 120, 144 and 168 [ Time Frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168 ]
    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
  • Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168 [ Time Frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168 ]
    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
  • Percent Change From Baseline in Fasting Triglycerides (TGs) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168 [ Time Frame: Parent Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, and 168 ]
    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
  • Percent Change From Baseline in Lipoprotein (a) at Weeks 48, 96, 144 and 168 [ Time Frame: Parent Baseline, Weeks 48, 96, 144, and 168 ]
    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
  • Percent Change From Baseline in Apolipoprotein-B (Apo-B) at Weeks 48, 96, 144, and 168 [ Time Frame: Parent Baseline, Weeks 48, 96, 144, and 168 ]
    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
  • Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Weeks 48, 96, 144, and 168 [ Time Frame: Parent Baseline, Weeks 48, 96, 144, and 168 ]
    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
  • Absolute Change From Baseline in Apo B/Apo A-1 Ratio at Weeks 48, 96, 144, and 168 [ Time Frame: Parent Baseline, Weeks 48, 96, 144, and 168 ]
    Baseline here corresponds to the baseline in the parent study (EFC12492, R727-CL-1112, EFC12732 or LTS11717). Post-baseline on-treatment data was obtained from Week 8 onwards up to Week 168 in this study.
  • Percent change from baseline in low density lipoprotein cholesterol (LDL-C) [ Time Frame: Up to 120 weeks ]
  • Percent change from baseline in other lipid parameters [ Time Frame: Up to 120 weeks ]
Not Provided
Not Provided
 
Open Label Study of Long Term Safety Evaluation of Alirocumab
Open-Label Extension Study of EFC12492, R727-CL-1112, EFC12732 and LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia

Primary Objective:

To assess the long-term safety of alirocumab (SAR236553/REGN727) when added to lipid-lowering therapy in participants with heterozygous familial hypercholesterolemia (heFH) who had completed EFC12492 (NCT01623115), R727-CL-1112 (NCT01709500), EFC12732 (NCT01617655) and LTS11717 (NCT01507831).

Secondary Objectives:

  • To evaluate the long-term efficacy of alirocumab on lipid parameters.
  • To evaluate the long-term immunogenicity of alirocumab.
The maximum study duration will be 176 weeks per participant.
Interventional
Phase 3
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Hypercholesterolemia
  • Drug: Alirocumab
    Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
    Other Names:
    • SAR236553
    • REGN727
    • Praluent
  • Drug: Lipid-Modifying Therapy (LMT)
    Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Experimental: Alirocumab 75 or 150 mg Q2W
Alirocumab 75 mg or 150 mg every 2 weeks (Q2W) added to stable lipid-modifying therapy (LMT) for up to 168 additional weeks (or until the product was commercially available) in participants who completed the parent studies EFC12492, R727-CL-1112, EFC12732 and LTS11717.
Interventions:
  • Drug: Alirocumab
  • Drug: Lipid-Modifying Therapy (LMT)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
986
1200
June 30, 2017
June 30, 2017   (Final data collection date for primary outcome measure)

Inclusion criteria:

Participants with heFH who had completed one of the four parent studies (EFC12492, R727-CL-1112, EFC12732 and LTS11717).

Exclusion criteria:

Significant protocol deviation in the parent study; Any permanent treatment discontinuation from the parent study.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Argentina,   Austria,   Belgium,   Bulgaria,   Canada,   Czechia,   Denmark,   Finland,   France,   Germany,   Hungary,   Israel,   Italy,   Mexico,   Netherlands,   Norway,   Portugal,   Romania,   Russian Federation,   South Africa,   Spain,   Sweden,   United Kingdom,   United States
Czech Republic
 
NCT01954394
LTS13463
2013-002572-40 ( EudraCT Number )
U1111-1143-3810 ( Other Identifier: UTN )
Yes
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Not Provided
Sanofi
Sanofi
Regeneron Pharmaceuticals
Study Director: Clinical Sciences & Operations Sanofi
Sanofi
June 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP